Mechanical thrombectomy (MT) has revolutionized the treatment of acute ischemic stroke (AIS) caused by large vessel occlusion (LVO) in the anterior circulation. While the initial guidelines focused on a narrow time window for intervention (typically within 6 hours of symptom onset), evolving research has expanded the therapeutic window, leading to the development of criteria like DAWN (DAWN trial) and DEFUSE 3 (DEFUSE 3 trial), which allow for MT even beyond the traditional 6-hour limit. This article will explore the implications of these expanded criteria, focusing on the concept of a "Hermes criteria" approach – a hypothetical synthesis incorporating the principles of DAWN, DEFUSE 3, and other relevant research to guide MT decisions in patients presenting beyond the standard 6-hour window but within a broader timeframe. We will examine the relevant guidelines, indications, imaging criteria, and clinical trial data supporting this extended approach.
Mechanical Thrombectomy Guidelines:
Current guidelines for MT are primarily based on the evidence from large randomized controlled trials (RCTs) such as EXTEND-IA, REVASCAT, and the aforementioned DAWN and DEFUSE 3 trials. These trials have significantly shaped the recommendations for patient selection and treatment protocols. Guidelines from organizations like the American Heart Association/American Stroke Association (AHA/ASA), the European Stroke Organisation (ESO), and other international bodies consistently emphasize the importance of rapid assessment and timely intervention for patients with AIS and LVO. These guidelines incorporate the evolving understanding of the ischemic penumbra – the area of salvageable brain tissue surrounding the infarct core – which is a crucial concept in determining eligibility for MT.
The core principle underlying these guidelines is the need for a balanced approach, weighing the potential benefits of MT against the risks of the procedure. This necessitates careful patient selection based on several factors, including the location and extent of the LVO, the time since symptom onset, and the patient's overall clinical condition. While the specific criteria may vary slightly among different guidelines, the common thread is the prioritization of patients with the highest likelihood of achieving significant neurological improvement with MT.
Mechanical Thrombectomy Indications:
The indications for MT are primarily defined by the presence of an LVO in the anterior circulation. This typically involves occlusion of the internal carotid artery (ICA), middle cerebral artery (MCA), or anterior cerebral artery (ACA). The precise location and extent of the occlusion are crucial for determining the suitability of MT. Imaging techniques, particularly CT angiography (CTA) and magnetic resonance angiography (MRA), are essential for identifying LVOs and assessing the perfusion status of the brain.
Beyond the presence of an LVO, the guidelines also consider other factors in determining the indications for MT. These include:
* Time since last known normal (LKN): While the traditional time window was 6 hours, the DAWN and DEFUSE 3 trials have extended this to 6-16 hours in select patients.
* Ischemic core volume: The size of the infarct core, as assessed by imaging, is an important consideration. Larger core volumes may indicate less potential for neurological recovery with MT.
* Penumbra volume: The presence of a substantial penumbra, representing salvageable brain tissue, is a strong indication for MT.
* Clinical presentation: The severity of the neurological deficit at presentation also plays a role. Patients with more severe deficits may still benefit from MT, but the likelihood of significant improvement may be lower.
current url：https://atjekn.e171z.com/bag/hermes-criteria-mechanical-thrombectomy-34595